Singapore-Israel Invests US$2.3m On Research Collaborations

singapore-israel-rnd-foundation

Tech & Pharma
July 20, 2011

Singapore and Israel are investing US$2.3 million through the Singapore-Israel Industrial R&D Foundation to kick start four new R&D projects.

AsianScientist (Jul. 20, 2011) – Singapore and Israel are investing US$2.3 million to kick start four new R&D projects between high-tech companies in both countries.

According to the Singapore-Israel Industrial R&D Foundation (SIIRD), a total of 60 research scientists and engineers from Singapore and Israel will be involved in four projects, which are estimated to generate cumulative revenues of US$205 million in the first three years of commercialization.

The SIIRD is a collaborative endeavor between the Singapore Economic Development Board and the Office of the Chief Scientist in Israel to promote, facilitate, and support joint industrial R&D projects between companies from both countries.

Funded projects include a Miniature Digital Scent Module, which is a micro-electro-mechanical system (MEMS) chip that detects scent, developed by Scentcom Ltd., an Israeli start-up, and Lynxemi Pte. Ltd., a Singapore product development and manufacturing company. By embedding the Module in handsets, home theater systems and mobile gaming devices, gamers and other device users will be able to enjoy a four-dimensional (4D) entertainment experience.

Lynxemi Pte. Ltd. is also partnering with an Israeli fabless semiconductor company, Wilocity Ltd., which develops 60 GHz multi-gigabit wireless chipsets, to increase the speed of wireless networking to more than ten times faster than the current highest Wi-Fi rate.

Traffix Systems, a Diameter protocol solutions vendor, and Elixir Technology Pte. Ltd., a Singapore software tools and services company, are developing an advanced Business Intelligence software that obtains business intelligence information by analyzing the signalling information of telecom networks.

Israeli skin treatment company, Kamedis Ltd., and Singapore-based biotech and fermentation company, AP Nutripharm (APN) Pte. Ltd., are working on producing a topical cream to treat a side effect of radiation therapy called radiation dermatitis, which can range from a mild skin rash to severe ulcerations. The Kamedis-APN cream will include herbal extracts and cordyceps fungi, and will be subject to in vitro assays and subsequent clinical studies.

SIIRD will also be raising the funding ceiling from the existing US$750,000 to US$1 million during their next round of project approvals in December. The Program will also expand beyond private sector companies to fund non-commercial research entities. The next deadline for project proposal submissions is September 9, 2011.

—–

Source: Singapore-Israel Industrial R&D Foundation.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

« « BACK
NEXT » »